NASDAQ:CLSN
Delisted
Celsion Corporation Stock News
$1.56
+0.0600 (+4.00%)
At Close: Jan 27, 2023
Celsion Corporation Announces Company Name Change to Imunon, Inc.
08:30pm, Monday, 19'th Sep 2022 GlobeNewswire Inc.
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines
Celsion Corporation Announces Company Name Change to Imunon, Inc.
05:30pm, Monday, 19'th Sep 2022
New name reflects the evolution of the Company’s business focus and its commitment to immunotherapies and vaccines LAWRENCEVILLE, N.J., Sept. 19, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDA
Celsion Corporation Announces Company Name Change to Imunon, Inc.
04:30pm, Monday, 19'th Sep 2022
New name reflects the evolution of the Company's business focus and its commitment to immunotherapies and vaccines
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
09:30am, Thursday, 15'th Sep 2022
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone LAWRENCEVILLE, N.J., Sept. 15, 2022 (GLOBE NEWSWIRE) —
Celsion Completes Enrollment of the Phase I/II OVATION 2 Study with GEN-1 in Advanced Ovarian Cancer
08:30am, Thursday, 15'th Sep 2022
110 Patients Enrolled in Study Comparing Novel Gene-Mediated Immunotherapy plus Neoadjuvant Chemotherapy versus Neoadjuvant Chemotherapy Alone
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m. ET on September 13
10:30pm, Monday, 12'th Sep 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Execut
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executiv
Celsion Corporation Presentation Time at the H.C. Wainwright 24th Annual Global Investment Conference Changed to 4:30 p.m.
06:30pm, Monday, 12'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company, announces that Dr. Corinne Le Goff, President and Chief Executiv
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
01:15pm, Wednesday, 07'th Sep 2022 GlobeNewswire Inc.
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief E
Celsion Corporation to Present at the H.C. Wainwright 24th Annual Global Investment Conference
09:15am, Wednesday, 07'th Sep 2022
LAWRENCEVILLE, N.J., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage drug development company today announced that Dr. Corinne Le Goff, President and Chief Exe
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
12:30pm, Thursday, 01'st Sep 2022 GlobeNewswire Inc.
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
09:30am, Thursday, 01'st Sep 2022
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model LAWRENCEVILLE, N.J., Sept. 01, 2022 (GLOBE NEWSWIRE) — Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on
Celsion Corporation Highlights Progress in its DNA-based Vaccine Program
08:30am, Thursday, 01'st Sep 2022
PLACCINE DNA-based Vaccine Demonstrates Robust Response in Murine Model
Celsion Corporation's (CLSN) CEO Corinne Le Goff on Q2 2022 Results - Earnings Call Transcript
03:31pm, Monday, 15'th Aug 2022
Celsion Corporation (NASDAQ:CLSN ) Q2 2022 Earnings Conference Call August 15, 2022 11:00 AM ET Company Participants Monique Kosse - IR, LifeSci Advisors Michael Tardugno - Executive Chairman Corinne
Celsion Corporation Reports Second Quarter 2022 Financial Results and Provides Business Update
08:30am, Monday, 15'th Aug 2022
DNA Mediated Immunotherapy and Next-Generation Vaccine Programs Supported with a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J., Aug. 15, 2022 (GLOBE NEWSWIRE)
